干旱区生态环境知识资源中心(Arid): Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic

Arid

DOI	10.2147/NDT.S394220
	Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic
	Haider, Batool; O'Sullivan, Amy K.; Bessonova, Leona; Keane, Elizabeth; Achtyes, Eric; Harvey, Philip; Kane, John M.; Saklad, Stephen R.; Trotter, Jeffrey P.; Claxton, Amy; Polak, Tiffany; McGrory, James; Noori, Wahidullah; Kessler, Asia Sikora; Yarlas, Aaron; Velligan, Dawn
通讯作者	Haider, B
来源期刊	NEUROPSYCHIATRIC DISEASE AND TREATMENT
EISSN	1178-2021
出版年	2023
卷号	19 页码:623-634
英文摘要	Purpose: The COVID-19 pandemic substantially impacted care of patients with schizophrenia treated with long-acting injectable antipsychotics (LAIs). This study (OASIS-MAPS) examined how clinical sites adapted operations and used telepsychiatry to maintain standard of care for these patients during the pandemic.Methods: Two online surveys (initial: October-November 2020, N = 35; follow-up: July-September 2021, N = 21) were completed by a principal investigator (PI) or PI-appointed designee at sites participating in the OASIS study (NCT03919994). Survey responses were analyzed descriptively.Results: At the time of the initial survey, all 35 participating sites were using variants of telepsychiatry, with 20 sites adopting it after the pandemic started. Most sites reported no negative impacts of the pandemic on medication adherence, although approximately 20% of sites reported decreased adherence for LAIs. Twelve sites (34%) reported switching patients with schizophrenia from LAIs to oral antipsychotic medications, while 11 sites (31%) reported switching patients from shorter to longer injection interval LAIs during the pandemic. Most sites did not experience difficulties in implementing or expanding telepsychiatry services, although lower reimbursement rate for telepsychiatry and patients' lack of access to and training on relevant technologies were the most frequently reported barriers.Conclusion: Changes made by sites after the pandemic onset were viewed by almost all participants as satisfactory for maintaining standard of care. Almost all participants thought that the use of telepsychiatry services would continue after the pandemic in a hybrid manner combining telepsychiatry and office visits. Ensuring that patients have equitable access to telepsychiatry will be important in the post-pandemic future.
英文关键词	telehealth coronavirus care management medication adherence
类型	Article
语种	英语
开放获取类型	gold, Green Published
收录类别	SCI-E
WOS记录号	WOS:000951709400001
WOS关键词	MENTAL-DISORDERS ; RISK ; MEDICATION ; PSYCHOSIS ; LOCKDOWN ; PEOPLE ; SPAIN
WOS类目	Clinical Neurology ; Psychiatry
WOS研究方向	Neurosciences & Neurology ; Psychiatry
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/397908
推荐引用方式 GB/T 7714	Haider, Batool,O'Sullivan, Amy K.,Bessonova, Leona,et al. Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic[J],2023,19:623-634.
APA	Haider, Batool.,O'Sullivan, Amy K..,Bessonova, Leona.,Keane, Elizabeth.,Achtyes, Eric.,...&Velligan, Dawn.(2023).Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic.NEUROPSYCHIATRIC DISEASE AND TREATMENT,19,623-634.
MLA	Haider, Batool,et al."Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic".NEUROPSYCHIATRIC DISEASE AND TREATMENT 19(2023):623-634.